Vazyme(688105) 中泰证券·2024-10-31 13:01Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative performance increase of over 15% compared to the benchmark index within the next 6 to 12 months [9]. Core Views - The company achieved a revenue of 986 million yuan in the first three quarters of 2024, representing a year-on-year growth of 13.42%. The net profit attributable to shareholders was 18 million yuan, with a significant year-on-year increase of 123.77% [1]. - The company is experiencing robust growth in its life sciences and biopharmaceutical sectors, with a steady performance in its IVD (in vitro diagnostics) business. The introduction of high-performance products and breakthroughs in overseas markets are expected to drive rapid growth in related reagent products [1][2]. - The company has actively expanded its overseas business since 2022, leveraging differentiated solutions that combine reagents, consumables, and equipment. This strategy has led to significant breakthroughs in North America, Europe, and Southeast Asia, enhancing delivery efficiency and contributing to revenue growth [1][2]. Summary by Sections Financial Performance - For Q3 2024, the company reported a revenue of 337 million yuan, a year-on-year increase of 12.87%. The net profit attributable to shareholders was 2 million yuan, a decline of 57.55% year-on-year, while the non-recurring net profit was -15 million yuan, showing a year-on-year growth of 30.88% [1][3]. - The gross profit margin for the first three quarters of 2024 was 70.48%, a slight decrease of 0.45 percentage points year-on-year. The net profit margin improved by 10.67 percentage points year-on-year to 1.73% [1][2]. Cost Management - The sales expense ratio for the first three quarters of 2024 was 34.21%, down by 3.70 percentage points year-on-year. The management expense ratio was 16.47%, a decrease of 3.43 percentage points, and the R&D expense ratio was 21.76%, down by 6.85 percentage points [1][2]. Growth Forecast - The revenue forecast for 2024-2026 is adjusted to 1.416 billion yuan, 1.779 billion yuan, and 2.191 billion yuan, respectively, with year-on-year growth rates of 10%, 26%, and 23%. The net profit attributable to shareholders is projected to be 33 million yuan, 196 million yuan, and 314 million yuan for the same period, with year-on-year growth rates of 147%, 493%, and 60% [1][2].